Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Lantern Pharma Inc. LTRN

Healthcare  —  Biotechnology
1.22 0.01 0.83% as of 25 Sep
Market cap
$15.5M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Lantern Pharma Inc. (LTRN) Business Profile

Updated before January 2025

Company Overview

Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage biotechnology company that leverages artificial intelligence (AI), machine learning (ML), and genomics to transform the development of precision oncology therapies. Founded in 2014 and headquartered in Dallas, Texas, Lantern Pharma aims to revolutionize cancer treatment by identifying and advancing therapies that are more effective, less toxic, and tailored to individual patients. The company was co-founded by Panna Sharma, who also serves as the President and CEO. Under Sharma’s leadership, Lantern Pharma has positioned itself as a pioneer in the integration of AI-driven insights into drug development, significantly reducing the time and cost associated with bringing new therapies to market.

Lantern Pharma’s mission is to harness the power of data and AI to unlock the potential of precision medicine in oncology. The company’s proprietary AI platform, RADR® (Response Algorithm for Drug Rescue and Repurposing), plays a central role in its operations, enabling the identification of biomarkers and patient populations most likely to benefit from specific therapies. This approach not only accelerates drug development but also enhances the likelihood of clinical success.

Core Business Segments

Lantern Pharma operates primarily in the field of oncology drug development, with a focus on leveraging AI and genomics to advance precision medicine. The company’s core business segments include:

1. Drug Development

Lantern Pharma’s pipeline consists of several promising oncology drug candidates, including:

  • LP-300: A small molecule drug candidate targeting non-small cell lung cancer (NSCLC) in non-smokers. LP-300 is designed to enhance the efficacy of chemotherapy by modulating oxidative stress pathways.
  • LP-184: A next-generation DNA-damage agent targeting solid tumors and central nervous system (CNS) cancers. LP-184 is being developed for indications such as glioblastoma, pancreatic cancer, and other hard-to-treat cancers.
  • LP-284: A drug candidate focused on hematologic malignancies, including non-Hodgkin’s lymphoma and multiple myeloma. LP-284 is designed to exploit vulnerabilities in cancer cells with specific genetic profiles.

2. AI-Driven Drug Discovery

The RADR® platform is Lantern Pharma’s flagship AI technology. RADR® integrates over 25 billion data points, including genomic, transcriptomic, and clinical data, to identify drug candidates, predict patient responses, and optimize clinical trial designs. This platform is a cornerstone of Lantern Pharma’s strategy to reduce the cost and time of drug development.

3. Partnerships and Collaborations

Lantern Pharma collaborates with academic institutions, research organizations, and pharmaceutical companies to advance its drug candidates and expand the capabilities of its RADR® platform. These partnerships enable the company to access cutting-edge research and accelerate the development of precision oncology therapies.

Business Model

Lantern Pharma’s business model is centered on the integration of AI-driven insights into oncology drug development. The company generates revenue through:

  • Drug Development and Licensing: Lantern Pharma advances its drug candidates through preclinical and early clinical stages, with the goal of licensing them to larger pharmaceutical companies for late-stage development and commercialization.
  • AI Platform Licensing: The RADR® platform is a valuable asset that can be licensed to other biotech and pharmaceutical companies for drug discovery and development.
  • Collaborative Research Agreements: Lantern Pharma engages in partnerships with academic and research institutions, generating revenue through collaborative projects and grants.

By leveraging AI and data analytics, Lantern Pharma aims to reduce the cost of drug development by up to 50% and accelerate timelines by several years, creating significant value for stakeholders.

Strategic Direction

Lantern Pharma is focused on several strategic priorities to drive future growth:

  • Pipeline Expansion: The company plans to expand its pipeline by identifying and advancing additional drug candidates using the RADR® platform. This includes exploring new indications and therapeutic areas.
  • Clinical Development: Lantern Pharma is committed to advancing its existing drug candidates, such as LP-300, LP-184, and LP-284, through clinical trials to demonstrate their safety and efficacy.
  • Global Expansion: The company aims to establish a global presence by entering new markets and forming strategic partnerships with international organizations.
  • Sustainability Goals: Lantern Pharma is dedicated to improving the sustainability of drug development by reducing waste, energy consumption, and resource utilization through its AI-driven approach.

Competitive Landscape

Lantern Pharma operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • AI-Driven Drug Development Companies: Companies like Exscientia, BenevolentAI, and Insilico Medicine are also leveraging AI and ML to accelerate drug discovery and development.
  • Precision Oncology Firms: Competitors such as Blueprint Medicines, Foundation Medicine, and Guardant Health focus on precision medicine and targeted therapies for cancer.
  • Traditional Pharmaceutical Companies: Large pharmaceutical companies like Pfizer, Merck, and Roche have significant resources and established oncology portfolios, posing competition in the broader cancer treatment market.

Lantern Pharma differentiates itself through its proprietary RADR® platform, which enables a data-driven approach to drug development, and its focus on rescuing and repurposing abandoned drug candidates.

Risk Factors

Lantern Pharma faces several risks that could impact its operations and financial performance:

  • Regulatory Risks: The company’s drug candidates must undergo rigorous regulatory approval processes, which are time-consuming and costly.
  • Market Dependence: Lantern Pharma’s success depends on the commercial viability of its drug candidates, which may face competition from existing therapies or new entrants.
  • Supply Chain Disruptions: The company relies on third-party manufacturers and suppliers, making it vulnerable to supply chain disruptions.
  • Technological Risks: The effectiveness of the RADR® platform depends on the quality and accuracy of the data it analyzes. Any issues with data integrity could impact drug development outcomes.
  • Financial Risks: As a clinical-stage company, Lantern Pharma has limited revenue streams and relies on external funding to finance its operations.

Recent Developments

Lantern Pharma has made significant progress in recent months, including:

  • Advancements in LP-184: The company announced promising preclinical data for LP-184, demonstrating its potential to treat glioblastoma and other CNS cancers.
  • Expansion of RADR® Platform: Lantern Pharma has added new data points and capabilities to its RADR® platform, enhancing its predictive accuracy and utility in drug discovery.
  • Collaborative Partnerships: The company has entered into new collaborations with academic institutions to explore novel applications of its drug candidates and AI platform.
  • COVID-19 Impact: While the pandemic posed challenges for clinical trials and supply chains, Lantern Pharma adapted by leveraging virtual tools and remote monitoring to maintain progress.

Investment Considerations

Lantern Pharma offers several strengths and risks for potential investors:

Strengths

  • Innovative Technology: The RADR® platform provides a competitive edge in AI-driven drug development.
  • Focused Pipeline: The company’s drug candidates target high-need areas in oncology, with significant market potential.
  • Cost Efficiency: Lantern Pharma’s AI-driven approach reduces the cost and time of drug development, enhancing its value proposition.

Risks

  • Early-Stage Company: As a clinical-stage company, Lantern Pharma has limited revenue and is not yet profitable.
  • Regulatory Uncertainty: The success of the company’s drug candidates depends on regulatory approvals, which are not guaranteed.
  • Market Competition: The biotechnology sector is highly competitive, with numerous players vying for market share.

Conclusion

Lantern Pharma Inc. is at the forefront of AI-driven precision oncology, leveraging its RADR® platform to transform the drug development process. With a promising pipeline, innovative technology, and a commitment to sustainability, the company is well-positioned to address unmet needs in cancer treatment. While challenges remain, including regulatory and financial risks, Lantern Pharma’s unique approach and strategic direction offer significant growth potential for investors and stakeholders.